TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Comparison of Outreach Methods to Encourage Enrollment in Diabetes Prevention and Weight Management Programs

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: HEALTH_SERVICES_RESEARCH
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Kaiser Permanente Member~* Age 18-75~* Prediabetes~* BMI \>= 25~* A1c 6.1-6.4%~* No dietitian visit within the past 3 years~Exclusion Criteria:~- Pregnancy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Usual care (Type: NO_INTERVENTION): Usual care
- Electronic health record gaps (Type: ACTIVE_COMPARATOR): Gaps will appear in the electronic health record and patient portal in order to prompt referral by provider or patient
- Bulk outreach (Type: ACTIVE_COMPARATOR): Gaps will appear in the electronic health record and patient portal in order to prompt referral by provider or patient; in addition a bulk letter or email will be sent
- Personalized outreach (Type: ACTIVE_COMPARATOR): Gaps will appear in the electronic health record and patient portal in order to prompt referral by provider or patient; in addition a bulk letter or email will be sent and patients will receive a personalized call by a registered dietitian

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of Obinutuzumab [RO5072759 (GA101)] in Combination With CHOP Chemotherapy in Patients With Previously Untreated Advanced Diffuse Large B-Cell Lymphoma (GATHER)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Adult patients, ≥18 years of age~* Previously untreated cluster of differentiation antigen 20 (CD20)-positive diffuse large B-cell lymphoma~* Ann Arbour Stage III/IV and bulky II (mass \>10 cm)~* At least one bi-dimensionally measurable lesion defined as \>1.5 cm in its largest dimension by CT scan~* Eastern Cooperative Oncology Group (ECOG) performance status 0, 1 or 2~* Left ventricular ejection fraction ≥50%~* Adequate hematologic function~Exclusion Criteria:~* Transformed lymphoma (follicular IIIB) if previously treated with chemotherapy or immunotherapy~* Prior therapy for diffuse large B-cell lymphoma except for nodal biopsy or local irradiation~* Central nervous system (CNS) lymphoma, primary mediastinal large cell lymphoma, primary cutaneous lymphoma, primary effusion lymphoma~* Patients who received cytotoxic drugs or rituximab as part of their treatment for another condition (e.g. rheumatoid arthritis) or prior use of an anti-CD20 antibody~* Chemotherapy or other investigational therapy within 28 days prior to the start of Cycle 1~* Contraindication to any of the individual components of CHOP, including prior receipt of anthracyclines~* History of severe allergic or anaphylactic reactions to monoclonal antibody therapy~* History of other malignancy, except for curatively treated basal or squamous cell carcinoma or melanoma of the skin or in situ carcinoma of the cervix, or malignancy treated with or without curative intent and in remission without treatment for ≥2 years prior to enrolment~* Positive for hepatitis B, hepatitis C, human immunodeficiency virus (HIV) or human T-cell leukemia virus (HTLV-1) infection~* Pregnant or lactating women

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- obinutuzumab + CHOP (Type: EXPERIMENTAL): Participants received 1000 mg obinutuzumab intravenously on Day 1 of each 21-day cycle for 8 cycles; during Cycle 1 administration also on Days 8 and 15. Participants also received standard CHOP therapy (cyclophosphamide, doxorubicin, vincristine and prednisone) for 6 cycles.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Bronchodilator Responsiveness in Obliterative Bronchiolitis

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Obliterative bronchiolitis (OB) following allogeneic HSCT~* FEV1 to slow inspiratory vital capacity (VC) ratio (FEV1/VC)\<5th percentile~* FEV1 \<75% predicted or absolute FEV1 fall \>10% of pre-HSCT value~* evidence of OB by computed tomography scanning~* negative microbiological yields in bronchoalveolar lavage fluid~* chronic graft-versus-host disease score \>0~* negative history for bronchial asthma, chronic obstructive pulmonary disease or other significant respiratory disease.~Exclusion Criteria:~* inability to perform lung function maneuvers~* pre-existent chronic lung disease other than OB

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- albuterol-tiotropium (Type: EXPERIMENTAL): At visit 1, lung function measurements will be performed in triplicate before and 90 min after inhaling four separate doses of 100 μg of albuterol (Ventolin®) and soon after 18 μg of tiotropium bromide \[Spiriva®\] to ensure maximal or near-maximal bronchodilation. Albuterol will be given by a metered-dose inhaler connected to a valved-holding chamber (Volumatic®) and tiotropium by a dry-powder device (Handihaler®).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: ACVBP Plus Rituximab Versus CHOP Plus Rituximab in Patients With Diffuse Large B-cell Lymphoma and Age-adjusted IPI of 1

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~Patient with histologically proven CD20+ diffuse large B-cell lymphoma (WHO classification) Aged from 18 to 59 years. Age-adjusted International Prognostic Index equal to 1 (elevated LDH level OR stage III-IV OR ECOG status 2-3-4).~Patient not previously treated. With a minimum life expectancy of 3 months. Negative HIV, HBV and HCV serologies test 4 weeks (except after vaccination). Having previously signed a written informed consent.~Exclusion Criteria:~Any other histological type of lymphoma. Any history of treated or non-treated indolent lymphoma. However, patients not previously diagnosed and having a diffuse large B-cell lymphoma with some small cell infiltration in bone marrow or lymph node may be included.~Central nervous system or meningeal involvement by lymphoma. Contra-indication to any drug contained in the chemotherapy regimens. Any serious active disease (according to the investigator's decision). Poor renal function (creatinin level\>150µmol/l), poor hepatic function (total bilirubin level\>30mmol/l, transaminases\>2.5 maximum normal level) unless these abnormalities are related to the lymphoma.~Poor bone marrow reserve as defined by neutrophils \<1.5 G/l or platelets \<100 G/l, unless related to bone marrow infiltration.~Any history of cancer during the last 5 years with the exception of non-melanoma skin tumors or stage 0 (in situ) cervical carcinoma.~Treatment with any investigational drug within 30 days before planned first cycle of chemotherapy and during the study.~Pregnant or lactating women. Adult patient under tutelage.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 59 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: DFMO in Children With Type 1 Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Males and females 12-40 years of age with a clinical diagnosis of T1D within 2 - 8 months after diagnosis at the time of visit 2.~2. Random non-fasting C-peptide level of \>0.2 pmol/mL at visit 1.~3. Positive for any one of the following diabetes-related autoantibodies (mIAA, GADA, IA-2A, or ZnT8A)~4. Treatment naïve of any immunomodulatory agent~5. Normal hearing at screening, defined as acceptable results of pure-tone audiometry (\<20 decibel \[dB\] baseline thresholds for frequencies 250, 500, 1000, and 2000 Hz~Exclusion Criteria:~1. Presence of severe, active disease that interferes with dietary intake or requires the use of chronic medication, with the exception of well-controlled hypothyroidism and mild asthma not requiring oral steroids. Presence of any psychiatric disorder that will affect ability to participate in study.~2. Diabetes other than T1D~3. Chronic illness known to affect glucose metabolism (e.g. Cushing syndrome, polycystic ovarian disorder, cystic fibrosis) or taking medications that affect glucose metabolism (e.g. steroids, metformin)~4. Inability to swallow pills~5. Psychiatric impairment or current use of anti-psychotic medication~6. Any condition that, in the investigator's opinion, may compromise study participation or may confound the interpretation of the study results.~7. Hematologic abnormalities at screening (anemia, leukopenia (particularly neutropenia), or thrombocytopenia)~8. Impaired renal function (assessed by history and BUN/Creatinine, DFMO is renally excreted)~9. Female participants of child-bearing age must not be pregnant and agree to use an effective form of birth control or be abstinent during the study period.~10. BMI \>95% for age and sex

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: 40 Years
- Healthy Volunteers: f

Study Arms:
- Difluoromethylornithine (Type: EXPERIMENTAL): Subjects may be given daily dose of DFMO
- Placebo (Type: PLACEBO_COMPARATOR): Subjects may be given daily dose of placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Bevacizumab for Neovascular Age-related Macular Degeneration

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Clinical diagnosis of neovascular Age-related macular degeneration~* Signed informed consent~Exclusion Criteria:~* No other ocular fundus diseases

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- Bevacizumab 1 (Type: ACTIVE_COMPARATOR): None
- Bevacizumab 2 (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Patients' Assessment of Satisfaction for Stroke Prevention in Atrial Fibrillation

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion criteria:~Cohort A (patients switched from VKA to Pradaxa)~* Written informed consent prior to participation.~* Female or male patients ≥ 20 years of age with a diagnosis of non-valvular atrial fibrillation (NVAF).~* At least 3 months of continuous VKA treatment for stroke prevention prior to baseline assessment.~* Patients switched to Pradaxa prior to baseline assessment according to the physician's discretion and the Summary of Product Characteristics (SmPCs)/reimbursement criteria.~OR Cohort B (patients newly initiated Pradaxa or VKA)~* Written informed consent prior to participation.~* Female or male patients ≥ 20 years of age, newly diagnosed with NVAF, and no previous treatment for stroke prevention (no use of any OAC within 1 year prior to enrolment).~* Patients initiated stroke prevention treatment with Pradaxa or VKA according to the physician's discretion and the SmPCs/reimbursement criteria.~Exclusion criteria:~* Contraindication to the use of Pradaxa® or VKA as described in the SmPCs.~* Patients receiving Pradaxa® or VKA for any other condition than stroke prevention in NVAF.~* Current participation in any clinical trial of a drug or device.~* Current participation in an AF-related registry, e.g. the Gloria AF program.

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Cohort A (Type: None): consented patients with NVAF in Taiwan with a previous VKA therapy, followed by switching to Pradaxa®
- Cohort B (Type: None): patients being newly diagnosed with NVAF and initiated on Pradaxa®

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Adjuvant Pemetrexed Plus Cisplatin for Adenocarcinoma of Lung

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Adenocarcinoma of Lung~* Postoperative pathologic stage IB\~IIIA~* Complete surgical resection (R0 resection) N1-2: R0 resection with lobectomy and mediastinal lymph nodes dissection (MLND) N0: R0 resection with lobectomy with or without MLND~* Adjuvant treatment should start between 4 to 6 weeks after surgery~* ECOG performance status 0-1~* Weight loss during last 3 months should be less than 10%.~* Normal hematologic, hepatic and renal function Neutrophil count \> 1500 /microliter, Platelet \> 100,000/microliter, Hemoglobin \> 9 g/dL Bilirubin \<=1.5 x upper limit normal, transaminase \< 2.5 x upper limit normal Serum Creatinine \<=1.5 mg/dL~* Women in child bearing age should consent using contraceptive measures, and must have negative pregnancy test.~Exclusion Criteria:~* Other malignant neoplastic disease within 5 years.~* Neoadjuvant chemotherapy before surgery of lung cancer~* Patients who will be treated with postoperative radiation.~* Stage IIIB or IV lung cancer~* Severe infection, or cardiorespiratory, hematologic illness~* HIV positive cases~* Pregnancy or lactating women~* Autoimmune diseases or those who receiving immune suppressive treatment~* Symptomatic neuropathy \> CTCAE grade 1~* Those who consented other clinical trials within 3 months~* Other significant medical conditions contraindicated to clinical trial

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Pemebit plus Cisplatin (Type: EXPERIMENTAL): Pemetrexed (Pemebit 500 mg/m2) plus cisplatin (75 mg/m2) every 3 weeks up to 4 cycles

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Chemotherapy and Radiation Therapy in Treating Patients With Non-Small Cell Lung Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: None
- Phase: PHASE1
- Number of Arms: None

Eligibility Criteria:
DISEASE CHARACTERISTICS: Histologically or cytologically confirmed non-small cell lung cancer (NSCLC) Stage IIIB or bulky stage IIIA not amenable to surgical resection Medically inoperable stage II or non-bulky stage IIIA Locally recurrent disease following surgery that is not amenable to further surgical resection No small cell carcinoma or mixed cytology No disease beyond radiation portal (T4 tumors with documented multifocal malignant pleural involvement or extension of supraclavicular nodal disease to cervical chain) No pleural effusion Pleural effusions visible on CT scan but not on chest x-ray that are inaccessible to thoracentesis or are cytologically negative are allowed Ineligible for enrollment on protocol RTOG 93-09~PATIENT CHARACTERISTICS: Age: 18 and over Performance status: ECOG 0-2 Karnofsky 50-100% Life expectancy: Not specified Hematopoietic: Absolute neutrophil count at least 2,000/mm3 Platelet count at least 100,000/mm3 Hepatic: Bilirubin no greater than 1.5 mg/dL No known Gilbert's disease Renal: Creatinine no greater than 1.5 mg/dL Calcium less than 12.0 mg/dL Cardiovascular: No symptomatic cardiovascular disease No active angina No congestive heart failure requiring active therapy No uncontrolled arrhythmias No myocardial infarction within the past 6 months Pulmonary: FEV1 at least 1.0 L unless cleared by radiation oncologist Other: Not pregnant Negative pregnancy test Fertile patients must use effective contraception for 3 months before study, during study, and for 3 months after study HIV negative No other concurrent active or invasive malignancy except nonmelanoma skin cancer Less than 10% unintended weight loss within 3 months of diagnosis No other concurrent medical condition that would preclude study No social situation or psychiatric disorder that would preclude study No active or uncontrolled infection No history of seizures No uncontrolled diabetes mellitus (random blood sugar at least 250 mg/dL)~PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: No prior chemotherapy for NSCLC No prior irinotecan or topotecan Endocrine therapy: Not specified Radiotherapy: No prior radiotherapy for NSCLC No prior radiotherapy to the chest Surgery: See Disease Characteristics Other: No concurrent phenytoin, phenobarbital, or other antiepileptic prophylaxis

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study to Compare Pediacel® to Infanrix®-IPV+Hib When Both Are Co-Administered With Prevenar® in Infants and Toddlers

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Infants 55 to 75 days old, inclusive on the day of first vaccination~* Born at full term of pregnancy (\> 37 weeks)~* Informed consent form signed by the parent(s) or the legal guardian~* Parents or the legal guardian able to read and write in the local language~* Parent(s) or the legal guardian able to attend all scheduled visits and to comply with the study procedures.~Exclusion Criteria:~* Presence of fever (defined as rectal body temperature ≥ 38.0°C) reported within the last 72 hours~* Moderate or severe acute illness with or without fever~* Participation in another clinical trial in the 30 days preceding first study vaccination~* Planned participation in another clinical trial during the present study period~* Received diphtheria, tetanus, pertussis, poliomyelitis, Haemophilus influenzae type b or a pneumococcal vaccine separately or in combination prior to study vaccination~* Received any vaccination in the 30 days preceding the first study vaccination and/or is planning any vaccination within 6 weeks following any of the study vaccinations~* Congenital or acquired humoral/cellular immunodeficiency or immunosuppressive therapy such as long-term systemic corticosteroids therapy (≥ 2 mg/kg/day prednisone equivalent for ≥ 14 days) in the previous 30 days~* Systemic or local hypersensitivity to any of the study vaccine components (including neomycin, streptomycin, polymyxin B and formaldehyde)~* History of life-threatening reaction(s) (such as encephalopathy, Hypotonic-Hyporesponsive Episode, rectal body temperature ≥ 40.0°C, convulsions with or without fever) to any vaccine containing the same components as the study vaccines~* Blood or blood-derived products (immunoglobulins) received since birth~* Known Human immunodeficiency virus (HIV) seropositivity~* Known thrombocytopenia or other bleeding disorder contraindicating intramuscular vaccination~* History of encephalopathy, seizures or progressive, evolving or unstable neurological condition~* Clinically significant findings on review of systems that might interfere with study vaccination or which, in the opinion of the Investigator, would interfere with the evaluation of the study vaccine/objectives or pose a health risk to the subject.

- Gender: ALL
- Minimum Age: 55 Days
- Maximum Age: 75 Days
- Healthy Volunteers: t

Study Arms:
- Group 1 (Type: EXPERIMENTAL): PEDIACEL co-administered with Prevenar
- Group 2 (Type: ACTIVE_COMPARATOR): Infanrix-IPV+Hib co-administered with Prevenar

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete